Abstract
Somatic activating mutations in EGFR identify a subset of non-small cell lung cancer that respond to tyrosine kinase inhibitors. Acquisition of drug resistance is linked to a specific secondary somatic mutation, EGFR T790M. Here we describe a family with multiple cases of non-small cell lung cancer associated with germline transmission of this mutation. Four of six tumors analyzed showed a secondary somatic activating EGFR mutation, arising in cis with the germline EGFR mutation T790M. These observations implicate altered EGFR signaling in genetic susceptibility to lung cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kris, M.G. et al. J. Am. Med. Assoc. 290, 2149–2158 (2003).
Lynch, T.J. et al. N. Engl. J. Med. 350, 2129–2139 (2004).
Paez, J.G. et al. Science 304, 1497–1500 (2004).
Pao, W. et al. Proc. Natl. Acad. Sci. USA 101, 13306–13311 (2004).
Sordella, R., Bell, D.W., Haber, D.A. & Settleman, J. Science 305, 1163–1167 (2004).
Kobayashi, S. et al. N. Engl. J. Med. 352, 786–792 (2005).
Pao, W. et al. PloS Med. 2, e73 (2005).
Kwak, E.L. et al. Proc. Natl. Acad. Sci. USA 102, 7665–7670 (2005).
Daub, H., Specht, K. & Ullrich, A. Nat. Rev. Drug Discov. 3, 1001–1010 (2004).
Yamamoto, M., Kurosu, T., Kakihana, K., Mizuchi, D. & Miura, O. Biochem. Biophys. Res. Commun. 319, 1272–1275 (2004).
Blencke, S., Ullrich, A. & Daub, H. J. Biol. Chem. 278, 15435–15440 (2003).
Blencke, S. et al. Chem. Biol. 11, 691–701 (2004).
Kosaka, T. et al. Cancer Res. 64, 8919–8923 (2004).
Han, S.-W. et al. J. Clin. Oncol. 23, 2493–2501 (2005).
Zhang, C. et al. Nat. Methods 2, 435–441 (2005).
Acknowledgements
We thank K. Shannon and J. Johns for assistance with specimen acquisition. This work was supported in part by the US National Institutes of Health (D.W.B., D.A.H.), the Doris Duke Foundation (D.A.H.), the National Foundation for Cancer Research (D.A.H.) and the V Foundation (J.S.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bell, D., Gore, I., Okimoto, R. et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37, 1315–1316 (2005). https://doi.org/10.1038/ng1671
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng1671
- Springer Nature America, Inc.
This article is cited by
-
Identification of Germline Mutations in East-Asian Young Never-Smokers with Lung Adenocarcinoma by Whole-Exome Sequencing
Phenomics (2023)
-
Two germline mutations can serve as genetic susceptibility screening makers for a lung adenocarcinoma family
Journal of Cancer Research and Clinical Oncology (2023)
-
The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations
Nature Communications (2022)
-
Quantitative Structure–Mutation–Activity Relationship Tests (QSMART) model for protein kinase inhibitor response prediction
BMC Bioinformatics (2020)
-
Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma
Scientific Reports (2020)